Literature DB >> 18346838

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Mauricette Michallet1, Quoc-Hung Le, Mohamad Mohty, Thomas Prébet, Franck Nicolini, Jean Michel Boiron, Hélène Esperou, Michel Attal, Noel Milpied, Bruno Lioure, Pierre Bordigoni, Ibrahim Yakoub-Agha, Jean-Henri Bourhis, Bernard Rio, Eric Deconinck, Marc Renaud, Zina Chir, Didier Blaise.   

Abstract

This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including >10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346838     DOI: 10.1016/j.exphem.2008.01.017

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Authors:  Wichai Chinratanalab; Nishitha Reddy; John P Greer; David Morgan; Brian Engelhardt; Adetola Kassim; Stephen J Brandt; Madan Jagasia; Stacey Goodman; Bipin N Savani
Journal:  Exp Hematol       Date:  2012-01-21       Impact factor: 3.084

2.  Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Authors:  Markus Ditschkowski; Ahmet H Elmaagacli; Rudolf Trenschel; Tanja Gromke; Nina K Steckel; Michael Koldehoff; Dietrich W Beelen
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

3.  Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.

Authors:  Patrice Chevallier; Myriam Labopin; Gérard Socié; Reza Tabrizi; Sabine Furst; Bruno Lioure; Thierry Guillaume; Jacques Delaunay; Régis Peffault de La Tour; Stéphane Vigouroux; Jean El-Cheikh; Didier Blaise; Mauricette Michallet; Karin Bilger; Noel Milpied; Philippe Moreau; Mohamad Mohty
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

Review 4.  Nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Brenda M Sandmaier
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

5.  Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Baron; M Labopin; D Blaise; L Lopez-Corral; S Vigouroux; C Craddock; M Attal; P Jindra; H Goker; G Socié; P Chevallier; P Browne; A Sandstedt; R F Duarte; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 6.  Thinking out of the box--new approaches to controlling GVHD.

Authors:  Frédéric Baron; Stéphanie Humblet-Baron; Grégory Ehx; Sophie Servais; Muriel Hannon; Ludovic Belle; Chantal Lechanteur; Alexandra Briquet; Olivier Giet; Etienne Baudoux; Evelyne Willems; Yves Beguin
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

7.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

8.  Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.

Authors:  Sharat Damodar; Ryan Shanley; Margaret MacMillan; Celalettin Ustun; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-14       Impact factor: 5.742

9.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; Mohamed L Sorror; Karl Blume; Dietger Niederwieser; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; Firoozeh Sahebi; Edward D Agura; Parameswaran Hari; Benedetto Bruno; Peter A McSweeney; Michael B Maris; Richard T Maziarz; Amelia A Langston; Wolfgang Bethge; Lars Vindeløv; Georg-Nikolaus Franke; Ginna G Laport; Andrew M Yeager; Kai Hübel; H Joachim Deeg; George E Georges; Mary E D Flowers; Paul J Martin; Marco Mielcarek; Ann E Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

Review 10.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nina Worel
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.